Noven Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Noven Pharmaceuticals's estimated annual revenue is currently $211.7M per year.
- Noven Pharmaceuticals's estimated revenue per employee is $197,438
Employee Data
- Noven Pharmaceuticals has 1072 Employees.
- Noven Pharmaceuticals grew their employee count by 4% last year.
Noven Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Quality | Reveal Email/Phone |
2 | VP and CFO | Reveal Email/Phone |
3 | VP Operations | Reveal Email/Phone |
4 | Head Marketing & Sales | Reveal Email/Phone |
5 | VP – Hisamitsu Group Strategy & Planning | Reveal Email/Phone |
6 | VP, QA and QC | Reveal Email/Phone |
7 | Director, Sales Training and Sales Operations Logistics | Reveal Email/Phone |
8 | Director, QA Compliance | Reveal Email/Phone |
9 | Senior Director, Biostatistics in Clinical Operations/Regulatory Department | Reveal Email/Phone |
10 | Director - IT Business Technology Services | Reveal Email/Phone |
Noven Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $26.5M | 132 | N/A | N/A | N/A |
#2 | $10.1M | 50 | 14% | N/A | N/A |
#3 | $282.6M | 1406 | N/A | N/A | N/A |
#4 | $13.9M | 69 | 44% | N/A | N/A |
#5 | $11.3M | 56 | 4% | N/A | N/A |
#6 | $11.5M | 57 | -7% | N/A | N/A |
#7 | $211.7M | 1072 | 4% | N/A | N/A |
#8 | $24.1M | 120 | 5% | N/A | N/A |
#9 | $7.8M | 39 | -2% | N/A | N/A |
#10 | $12.9M | 64 | -2% | N/A | N/A |
What Is Noven Pharmaceuticals?
Noven Pharmaceuticals, Inc. (Nasdaq: NOVN), headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Our principal growth strategy is to apply our patented DOT Matrix® transdermal technology across diverse therapeutic categories with strong industry partners. Our patches are sold in over 30 countries, and a range of new prescription patches are under development. Together with Novartis Pharmaceuticals Corporation, we own Novogyne Pharmaceuticals, a successful women’s health products company with net sales of over $100 million in 2003. Novogyne’s lead product is Vivelle Dot® (estradiol transdermal system) – the smallest estrogen patch in the world and the most dispensed estrogen patch in the U.S. With the most advanced transdermal technology on the market, we are committed to expanding the universe of transdermal therapies for the benefit of patients, industry partners and shareholders.
keywords:N/A
N/A
Total Funding
1072
Number of Employees
$211.7M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Noven Pharmaceuticals News
... Janssen Pharmaceuticals, NEOS Therapeutics, Rhodes Pharmaceuticals, Noven Therapeutics, Ironshore Pharmaceuticals, Lannett Company,...
Noven Pharmaceuticals, Novartis AG, Sottepolle, BioTE Medical, Pfizer Inc., TherapeuticsMD Inc, Bayer AG, Novo Nordisk A/S, Others.
... Nitto Denko Corporation, Noven Pharmaceuticals Inc. (Hisamitsu Pharmaceutical Co. Inc.), Prosolus Inc., Samyang Holdings Corporation,...
Noven Pharmaceuticals, a Miami developer of drug-patch technologies and products, agreed to acquire privately held JDS Pharmaceuticals of New York for $125 million. JDS specializes in neurological drugs, including its antidepressant Pexeva and a timed-release form of lithum for bipolar disorder. ...